112 related articles for article (PubMed ID: 6539169)
1. Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors.
Sinkule JA; Hutson P; Hayes FA; Etcubanas E; Evans W
Cancer Res; 1984 Jul; 44(7):3109-13. PubMed ID: 6539169
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
Hande KR; Wedlund PJ; Noone RM; Wilkinson GR; Greco FA; Wolff SN
Cancer Res; 1984 Jan; 44(1):379-82. PubMed ID: 6690051
[TBL] [Abstract][Full Text] [Related]
3. Teniposide (VM26) disposition in children with leukemia.
Sinkule JA; Stewart CF; Crom WR; Melton ET; Dahl GV; Evans WE
Cancer Res; 1984 Mar; 44(3):1235-7. PubMed ID: 6581866
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.
D'Incalci M; Rossi C; Zucchetti M; Urso R; Cavalli F; Mangioni C; Willems Y; Sessa C
Cancer Res; 1986 May; 46(5):2566-71. PubMed ID: 3697995
[TBL] [Abstract][Full Text] [Related]
5. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
Lowis SP; Pearson AD; Newell DR; Cole M
Cancer Res; 1993 Oct; 53(20):4881-9. PubMed ID: 8402676
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.
Sonnichsen DS; Ribeiro RC; Luo X; Mathew P; Relling MV
Clin Pharmacol Ther; 1995 Jul; 58(1):99-107. PubMed ID: 7628187
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics of etoposide short-term infusions within the scope of the GPOH therapy protocol].
Boos J; Real E; Schulze-Westhoff P; Pröbsting B; Wolff J; Jürgens H
Klin Padiatr; 1993; 205(4):288-94. PubMed ID: 8377449
[TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of etoposide in gestochoriocarcinoma.
D'Incalci M; Sessa C; Rossi C; Roviaro G; Mangioni C
Cancer Treat Rep; 1985 Jan; 69(1):69-72. PubMed ID: 2981622
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in children with cancer.
Rivera G; Evans WE; Dahl GV; Yee GC; Pratt CB
Cancer Res; 1980 Nov; 40(11):4250-3. PubMed ID: 6258775
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
Kearns CM; Blakley RL; Santana VM; Crom WR
Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of vincristine sulfate in adult cancer patients.
Sethi VS; Jackson DV; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Spurr CL
Cancer Res; 1981 Sep; 41(9 Pt 1):3551-5. PubMed ID: 7260915
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of vinblastine by continuous intravenous infusion.
Lu K; Yap HY; Loo TL
Cancer Res; 1983 Mar; 43(3):1405-8. PubMed ID: 6825110
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
Tan CT; Hancock CH; Mondora A; Hoffman NW
Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).
Stewart DJ; Benjamin RS; Zimmerman S; Caprioli RM; Wallace S; Chuang V; Calvo D; Samuels M; Bonura J; Loo TL
Cancer Res; 1983 Feb; 43(2):917-20. PubMed ID: 6681533
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies.
Gregianin LJ; Brunetto AL; Di Leone L; Costa TD; Santos PP; Schwartsmann G
Med Sci Monit; 2002 Sep; 8(9):PI70-7. PubMed ID: 12218955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
